Merck has decided to halt all research operations in the UK and abandon its planned $1.3 billion London research center, citing insufficient governmental support for life sciences investment and drug pricing policies. This move represents a significant setback for the UK’s ambitions to boost its life sciences sector and underscores pharma industry frustrations over the NHS’s drug reimbursement schemes. The decision includes 125 layoffs related to R&D closures.